Literature DB >> 11884500

In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C--specific ligand.

Henry R Wolfe1, Marivi Mendizabal, Elinor Lleong, Alan Cuthbertson, Vinay Desai, Shirley Pullan, Dennis K Fujii, Matthew Morrison, Richard Pither, Scott A Waldman.   

Abstract

UNLABELLED: Guanylyl cyclase C (GC-C) is a transmembrane receptor expressed by human intestinal cells and primary and metastatic colorectal adenocarcinomas but not by extraintestinal tissues or tumors. The Escherichia coli heat-stable enterotoxin analog, STa (5--18), is a 14--amino acid peptide that selectively binds to the extracellular domain of GC-C with subnanomolar affinity. This study examined the utility of a radiolabeled conjugate of STa (5--18) to selectively target and image extraintestinal human colon cancer xenografts in vivo in nude mice.
METHODS: The STa conjugate, ethoxyethyl-mercaptoacetamidoadipoylglycylglycine-STa (5--18) (NC100586), was synthesized and labeled with (99m)Tc to produce (99m)Tc-NC100586. This compound was intravenously administered to nude mice bearing human colon cancer xenografts, and specific targeting was evaluated by biodistribution and gamma camera imaging.
RESULTS: In CD-1 nude mice, biodistribution and scintigraphic imaging analyses showed selective uptake of (99m)Tc-NC100586 into human colon cancer xenografts that express GC-C but not into normal tissues that do not express GC-C. Similarly, (99m)Tc-NC100586 injected intravenously into CD-1 nude mice with human colon cancer hepatic metastases selectively accumulated in those metastases, and about 5-mm foci of tumor cells were visualized after ex vivo imaging of excised livers. Accumulation of (99m)Tc-NC100586 in human colon cancer xenografts reflected binding to GC-C because (99m)Tc-NC100588, an inactive analog that does not bind to GC-C, did not selectively accumulate in cancer xenografts compared with normal tissues. Also, coadministration of excess unlabeled STa (5--18) prevented accumulation of (99m)Tc-NC100586 in human colon cancer xenografts. Furthermore, (99m)Tc-NC100586 did not selectively accumulate in Lewis lung tumor xenografts, which do not express GC-C.
CONCLUSION: This study showed that intravenously administered STa (5--18) selectively recognizes and binds to GC-C expressed by human colon cancer cells in vivo. Also shown was the ability to exploit this selective interaction to target imaging agents to extraintestinal human colon tumors in nude mice. These results suggest the utility of STa and GC-C for the development of novel targeted imaging and therapeutic agents with high specificity for metastatic colorectal tumors in humans.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11884500

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

1.  Comparative evaluation of three 64Cu-labeled E. coli heat-stable enterotoxin analogues for PET imaging of colorectal cancer.

Authors:  Dijie Liu; Douglas Overbey; Lisa D Watkinson; Charles J Smith; Said Daibes-Figueroa; Timothy J Hoffman; Leonard R Forte; Wynn A Volkert; Michael F Giblin
Journal:  Bioconjug Chem       Date:  2010-07-21       Impact factor: 4.774

Review 2.  E. coli heat-stable enterotoxin and guanylyl cyclase C: new functions and unsuspected actions.

Authors:  Ralph A Giannella; Elizabeth A Mann
Journal:  Trans Am Clin Climatol Assoc       Date:  2003

3.  Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.

Authors:  Khaldoun Almhanna; Maria Luisa Limon Miron; David Wright; Antonio Cubillo Gracian; Richard A Hubner; Jean-Luc Van Laethem; Carolina Muriel López; Maria Alsina; Frederico Longo Muñoz; Johanna Bendell; Irfan Firdaus; Wells Messersmith; Zhan Ye; Adedigbo A Fasanmade; Hadi Danaee; Thea Kalebic
Journal:  Invest New Drugs       Date:  2017-02-11       Impact factor: 3.850

4.  A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.

Authors:  Khaldoun Almhanna; David Wright; Teresa Macarulla Mercade; Jean-Luc Van Laethem; Antonio Cubillo Gracian; Carmen Guillen-Ponce; Jason Faris; Carolina Muriel Lopez; Richard A Hubner; Johanna Bendell; Alain Bols; Jaime Feliu; Naureen Starling; Peter Enzinger; Devalingham Mahalingham; Wells Messersmith; Huyuan Yang; Adedigbo Fasanmade; Hadi Danaee; Thea Kalebic
Journal:  Invest New Drugs       Date:  2017-05-19       Impact factor: 3.850

Review 5.  Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.

Authors:  Allison A Aka; Jeff A Rappaport; Amanda M Pattison; Takami Sato; Adam E Snook; Scott A Waldman
Journal:  Expert Rev Clin Pharmacol       Date:  2017-04-10       Impact factor: 5.045

6.  Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity.

Authors:  Adam E Snook; Benjamin J Stafford; Peng Li; Gene Tan; Lan Huang; Ruth Birbe; Stephanie Schulz; Matthias J Schnell; Mathew Thakur; Jay L Rothstein; Laurence C Eisenlohr; Scott A Waldman
Journal:  J Natl Cancer Inst       Date:  2008-06-24       Impact factor: 13.506

7.  STa peptide analogs for probing guanylyl cyclase C.

Authors:  Xiaobing Tian; Allison M Michal; Peng Li; Henry R Wolfe; Scott A Waldman; Eric Wickstrom
Journal:  Biopolymers       Date:  2008       Impact factor: 2.505

8.  Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.

Authors:  Michael S Magee; Tara S Abraham; Trevor R Baybutt; John C Flickinger; Natalie A Ridge; Glen P Marszalowicz; Priyanka Prajapati; Adam R Hersperger; Scott A Waldman; Adam E Snook
Journal:  Cancer Immunol Res       Date:  2018-04-03       Impact factor: 11.151

9.  Colorectal cancer is a paracrine deficiency syndrome amenable to oral hormone replacement therapy.

Authors:  P Li; J E Lin; A E Snook; A V Gibbons; D S Zuzga; S Schulz; G M Pitari; S A Waldman
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

10.  Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.

Authors:  John C Flickinger; Jeffrey A Rappaport; Joshua R Barton; Trevor R Baybutt; Amanda M Pattison; Adam E Snook; Scott A Waldman
Journal:  Biomark Med       Date:  2021-01-20       Impact factor: 2.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.